We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Apple stock lifted following guidance for the current quarter after the company reported a drop in ​iPhone and China sales.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

BofA Securities analyst Vivek Arya maintained a Buy rating on Nvidia Corp (NASDAQ:NVDA) with a price target of $190.

Blaize's innovative product pipeline, built on its full-stack programmable processor architecture suite and software platform for AI processing, has resulted in an increasingly robust and growing ...

The sports bar chain, which is now publicly traded, leans on its menu diversity, service model and alcohol mix to target $1 ...

Proliferating and prevailing technology is not a legacy and heritage of any country or a person, while accessible and ...

Novartis said this morning that its pipeline ... sales projections for a sweep of its current drugs – including Cosentyx, Kisqali, Kesimpta, Pluvicto, and Leqvio – and more than 15 data ...

The NAV model indicates BNTX is trading at a premium, reinforcing the hold rating amidst financial and pipeline uncertainties ... all the other data was obtained from the company’s filings ...

Artificial intelligence pushed many stock prices higher, but these three remain particularly attractive for investors.